Microbiome New Degradation Strategy Revives a Long-Standing Immuno-Oncology TargetBy adminJanuary 9, 20260 Credit: PASIEKA/Getty Images For more than a decade, targeted protein degradation has reshaped how scientists think about drugging disease. Instead…
DNA & Genetics Moleculent’s Early Access Program Tests Its Cell-Cell Mapping Tech on Immuno-OncologyBy adminNovember 9, 20250 When asked what Moleculent’s cell-cell interaction mapping technology provides to translational researchers, CEO Olle Ericsson explained that it adds “a…
